Holds lifted for two Opdivo MM trials

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA lifted partial holds following protocol amendments to the Phase I CheckMate -039 and Phase II CA204142 trials evaluating Opdivo nivolumab (BMS-936558, MDX-1106, ONO-4538) in combination with immuno-modulatory medicines (IMiDs) to treat relapsed or refractory multiple myeloma (MM). BMS declined to disclose details on the amendments.

The company said a partial hold remains on the Phase III CheckMate -602 trial of Opdivo combinations in MM patients...